



In association with

Deloitte.



US HEALTHCARE AND LIFE SCIENCES CONFERENCE

May 6, 2015
Metropolitan Club, New York

live.ft.com/ushc2015



@FTLive #FTUSHC

Lead Sponsor



Luncheon Sponsor



An event from FINANCIAL TIMES **LIVE**

US HEALTHCARE AND LIFE SCIENCES CONFERENCE

The healthcare and life sciences industry is facing a time of both tumultuous change and momentous opportunity. In the US, healthcare reform has reached a new level of maturity and is beginning to transform the landscape of the industry for payers, providers and patients. The biotechnology industry is on the rise, and has been leading the way in deal making and important drug launches. Meanwhile the industry is gradually waking up to the opportunities and disruptive threats of digital health as the wearable craze takes hold, health apps proliferate and big data becomes a reality. With so much change and innovation underway, are we now at the cusp of a major transformation of the healthcare system? What does the future hold?



TOPICS TO BE DISCUSSED INCLUDE:

- Growth and transformation strategies at the intersection of change: M&A and beyond
- Aging, disease and the secrets of longevity
- The potential and perils of digital health and cyber security
- Pricing and reimbursement: surviving and thriving in a value based world

WHO SHOULD ATTEND?

This event is for: CEOs, CFOs, CIOs, Chief Medical Officers, Chief Strategy Officers, Heads of R&D, Emerging Markets, Consumer Health, Government Relations, Pricing, Regulation, Market Access, etc. and other senior-level executives in the following sectors:

- Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies
- Medical Devices and Diagnostics
- Investment (Fund Managers, Venture Capitalists, Private Equity firms, Investment Bankers, IP Groups)
- Legal Counsel
- Healthcare IT (Patient records, data, mobile healthcare applications, social media)
- Regulation

US HEALTHCARE AND LIFE SCIENCES CONFERENCE

CONFERENCE AGENDA

WEDNESDAY, MAY 6, 2015 | THE METROPOLITAN CLUB, NEW YORK

8:00 am **Registration and Breakfast**

9:00 am **Opening Remarks**

Andrew Ward, Pharmaceuticals Correspondent, *Financial Times*

9:05 am **At the Cusp? Healthcare and the Future**

Healthcare reform in the US is reaching a new level of maturity, with a growing realization that despite the ebb and flow of political maneuvering and change, reversal is unlikely and reform is here to stay. At this important juncture, what can we ascertain about how reform will transform the healthcare market in the US? Will we succeed in bending the cost curve? Will the US in the longer term move towards a universal, single payer system? Will employers become disengaged from healthcare provision? And what can be said more generally about how healthcare will be transformed in the years ahead? With significant innovations and progress underway in the field of genomics, biotechnology, digital and health technologies and age-related disease research for instance, are we nearing a tipping point of a major transformation of healthcare? Which diseases and health challenges will today's Millennials face that their parents didn't? Will dealing with the label of pre-clinical disease, for instance, become the major health dilemma for the next generation? As new models and provider of care proliferate, will the patient-doctor relationship become medicine's fastest fading commodity?

SPEAKERS:

Dr Troyen Brennan, Chief Medical Officer, *CVS Health*

Helen Darling, Strategic Adviser, Former President and CEO, *National Business Group on Health*

Malay Gandhi, Managing Director, *Rock Health*

Dr John Rowe, Professor, *Columbia University Medical School*

Christi Shaw, US Country Head, *Novartis*, President, *Novartis Corporation*

MODERATED BY:

Andrew Ward, Pharmaceuticals Correspondent, *Financial Times*

10:05 am **Pricing and Reimbursement: Surviving and Thriving in a Value Based World**

With the recent launch of Gilead's Solvadi, a new hepatitis C drug at a cost of \$ 84,000 for a 12 week course, a political debate in the US over drug pricing was unleashed, marked by what amounts to a national rebellion against the company and its drug. With the use of such high price specialty drugs expected to rise, and pressure to curtail costs increasing, is the Solvadi case a harbinger of greater scrutiny of drug pricing in the US from payers, politicians and the public? How much is too much? Will companies have to accept lower prices than expected for specialty medicines? Will we see drug rationing with a body such as NICE in the UK, or something comparable, emerging as a gatekeeper for new medicines? Are market forces/prices the only effective way to drive medical innovation? What role could risk sharing and other value based pricing models play?

SESSION KEYNOTE:

Dr Todd Hobbs, Chief Medical Officer, *Novo Nordisk*, North America

SPEAKERS:

Dr Peter Bach, Director, Center for Health Policy and Outcomes, *Memorial Sloan Kettering Cancer Center*

Paul Hudson, President, *AstraZeneca US* and EVP, North America, *AstraZeneca*

John LaMattina, Senior Partner, *PureTech Ventures*

Dr Joshua Ofman, Senior Vice President, Global Value and Access, *Amgen*

MODERATED BY:

David Crow, Senior US Business Correspondent, *Financial Times*

11:05 am **Networking Break**

11:25 am **Keynote Interview**

Paul Hudson, President, *AstraZeneca US* and EVP, North America, *AstraZeneca*

11:50 am **Growth and Transformation Strategies at the Intersection of Change: M&A and Beyond**

Anyone witnessing the feverish deal-making that has swept through the global life sciences and healthcare industry recently might conclude that M&A activity has become the dominant force shaping the industry. M&A, however, is just one way forward, as companies respond to change in this dynamic and innovative space. Companies are embracing a variety of approaches including investments in emerging markets, collaborations and partnerships, including with new players outside the healthcare sector in their quest for growth. What forces have been driving M&A, and are they here to stay? Has recent M&A been opportunistic or 'retooling for next decade'? Which types of deals will yield the greatest value? To what extent might regulatory and political scrutiny limit the efficiencies that can be achieved in M&A deals? Will we see more deals between big pharma rivals-what are the risk of such deals, and are they set to become commonplace? What are the patient engagement strategies healthcare companies are undertaking to ensure patient are 'front and centre' to their business? Where are companies looking for tomorrow's progressive growth, and what do the 'bets' new entrants are placing in the industry tell us about where future growth may come from?

SESSION KEYNOTE:

Geno Germano, Group President, Global Innovative Pharma Business, *Pfizer*

SPEAKERS:

Dr Rodney Hochman, President and CEO, *Providence Health & Services*

Dr Jeremy Levin, Chairman, *Ovid Therapeutics*

Dame Louise Makin, Chief Executive Officer, *BTG plc*

Jamey Millar, SVP, Policy and Payers, *GlaxoSmithKline*

MODERATED BY:

Reynold W. (Pete) Mooney, Global Managing Director, Life Sciences and Health Care, *Deloitte*

12:50 pm **Lunch**

SPONSORED BY:



David Cordani, President and CEO, *Cigna Corporation*

2:00 pm **Aging, Disease and the Secrets of Longevity**

A growing number of healthcare companies and investment capital is making its way into the study of aging with the aim not only of extending lifespan-or healthspan as it is more appropriately known-but also of studying the link between the processes of aging and the many diseases which afflict old age to include Alzheimer's, heart disease and chronic diseases such as diabetes. What lies ahead could be a future in which centenarians could become the norm rather than the exception-when aging could possibly be 'cured', resulting in a less crippling and costly burden on the healthcare system. Where is research heading and what have been the strategies behind the companies making a move into this growing field? What new ways might emerge of diagnosing, understanding and addressing the diseases of aging? Given the lack of significant progress in tackling degenerative diseases such as Alzheimer's and Parkinson's to date, what is the case for thinking success is achievable now, and what is timeline for the availability of new anti-aging medicines? What are the practical and philosophical challenges which need to be addressed before the development of anti-aging drugs arrives in earnest? With regards to the here and now business of Alzheimer's, how realistic are the government goals of a disease-modifying medicine by 2025? Will investment incentives and extended patents be made available?

SPEAKERS:

Aubrey de Grey, Chief Science Officer, *SENS Research Foundation*

Felix Frueh, Chief Scientific Officer, *Human Longevity*

Drew Holzapfel, Executive Director, *Global CEO Initiative on Alzheimer's Disease*

Jay Olshansky, Professor, *University of Illinois at Chicago*

Dr Michael Severino, Executive Vice President, Research & Development and Chief Scientific Officer, *AbbVie*

MODERATED BY:

Andrew Ward, Pharmaceuticals Correspondent, *Financial Times*

3:00 pm **The Potential and Perils of Digital Health and Cyber Security**

The wearables craze is well established, health apps are proliferating and big data is becoming a reality. Where next in the convergence of health and digital technology? Do deals such as Novartis-Google and Abbvie-Calico signal that big pharma is waking up to the opportunities and disruptive threats of digital health? One of the unintended consequences of the digitisation of healthcare and increasingly networked connectivity, however, is the heightened risk of cyber-attack compromising the availability, integrity and confidentiality of private health information, with resultant damage to reputation and brand, and the loss of patient goodwill. The healthcare industry was subjected to the largest (43%) of cyber-attacks of any industry in 2013, a 30 % increase in the previous year. Will considerations of cyber security and privacy stop the digital revolution in its tracks? What are the capability gaps of healthcare companies, and how should this challenge be addressed?

SPEAKERS:

Brian Cincera, VP, Global Information Security, *Pfizer*

Walter de Brouwer, Founder and CEO, *Scanadu*

Pierre-Alexandre Fournier, Co-founder and CEO, *Hexoskin*

Jennifer Malatesta, Principal, *Deloitte*

MODERATED BY:

David Crow, Senior US Business Correspondent, *Financial Times*

4:00 pm **Closing Remarks**

For the latest agenda please visit: live.ft.com/ushc2015

REGISTRATION FEES

Delegate Rates	Fee
Standard rate	\$1195
Government/Non-profit rate	\$495

Group rates are also available. Please email chrissy.mcnasby@ft.com for more information.

HOW TO REGISTER:

live.ft.com/ushc2015

CONTACT INFORMATION

REGISTRATION, MEDIA PARTNER & PRESS INQUIRIES

Chrissy McNasby

T +1 917 551 5101

E chrissy.mcnasby@ft.com

SPONSORSHIP OPPORTUNITIES

Tim Powell

T +1 917 551 5097

E tim.powell@ft.com

VENUE INFORMATION



The Metropolitan Club

One East 60th Street (at Fifth Avenue)
New York, NY 10022

T +1 212 838 7400

W www.metropolitanclubnyc.org